MLYS
Mineralys Therapeutics, Inc.
Biotechnology
Market Cap$2.00B
5Y Perf.+69.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MLYS vs SPRB
Revenue, margins, valuation, and 5-year total return — side by side.
SPRB
Spruce Biosciences, Inc.
Biotechnology
Market Cap$79M
5Y Perf.-66.0%
MLYS vs SPRB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MLYS | SPRB |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2.00B | $79M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-152M | $-39M |
| Total Debt | $0.00 | $736K |
| Cash & Equiv. | $173M | $49M |
MLYS vs SPRB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MLYS
SPRB
| Stock | Feb 23 | May 26 | Return |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | 100 | 169.4 | +69.4% |
| Spruce Biosciences,… (SPRB) | 100 | 34.0 | -66.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MLYS vs SPRB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MLYS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Spruce Biosciences, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
MLYS
Mineralys Therapeutics, Inc.
The Long-Run Compounder
MLYS carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 63.3% 10Y total return vs SPRB's -95.5%
- 19.5% revenue growth vs SPRB's -100.0%
- 2.4% margin vs SPRB's -0.2%
Best for: long-term compounding
SPRB
Spruce Biosciences, Inc.
The Income Pick
SPRB is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.75
- Rev growth -100.0%, EPS growth 47.5%
- Lower volatility, beta 0.75, Low D/E 1.7%, current ratio 5.17x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MLYS | 19.5% revenue growth vs SPRB's -100.0% |
| Quality / Margins | MLYS | 2.4% margin vs SPRB's -0.2% |
| Stability / Safety | SPRB | Beta 0.75 vs MLYS's 0.77 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SPRB | +9.9% vs MLYS's +108.3% |
| Efficiency (ROA) | MLYS | -27.0% ROA vs SPRB's -128.0% |
MLYS vs SPRB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMLYSLAGGINGSPRB
SPRBSpruce Biosciences, I…
1leads
MLYSMineralys Therapeutic…
2leads
6 Total Categories
CATEGORYLEADERvs SPRBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SPRB1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MLYS5/5
Total Returns1Y, 3Y, 5Y total returns with dividends
MLYS5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SPRB leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MLYS and SPRB operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | MLYSMineralys Therape… | SPRBSpruce Bioscience… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$171M | -$36M |
| Net IncomeAfter-tax profit | -$152M | -$39M |
| Free Cash FlowCash after capex | -$136M | -$33M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +40.5% | +75.5% |
SPRB leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MLYS and SPRB each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MLYSMineralys Therape… | SPRBSpruce Bioscience… |
|---|---|---|
| Market CapShares × price | $2.0B | $79M |
| Enterprise ValueMkt cap + debt − cash | $1.8B | $31M |
| Trailing P/EPrice ÷ TTM EPS | -13.15x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 3.15x | 1.04x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MLYS and SPRB each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MLYS leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
MLYS delivers a -27.9% return on equity — every $100 of shareholder capital generates $-28 in annual profit, vs $-2 for SPRB.
| Metric | MLYSMineralys Therape… | SPRBSpruce Bioscience… |
|---|---|---|
| ROE (TTM)Return on equity | -27.9% | -2.0% |
| ROA (TTM)Return on assets | -27.0% | -128.0% |
| ROICReturn on invested capital | -46.4% | — |
| ROCEReturn on capital employed | -40.7% | -100.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | -$173M | -$48M |
| Cash & Equiv.Liquid assets | $173M | $49M |
| Total DebtShort + long-term debt | $0 | $736,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -392.62x |
MLYS leads this category, winning 5 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
MLYS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MLYS five years ago would be worth $16,334 today (with dividends reinvested), compared to $495 for SPRB. Over the past 12 months, SPRB leads with a +985.7% total return vs MLYS's +108.3%. The 3-year compound annual growth rate (CAGR) favors MLYS at 23.1% vs SPRB's -30.2% — a key indicator of consistent wealth creation.
| Metric | MLYSMineralys Therape… | SPRBSpruce Bioscience… |
|---|---|---|
| YTD ReturnYear-to-date | -15.7% | -36.2% |
| 1-Year ReturnPast 12 months | +108.3% | +985.7% |
| 3-Year ReturnCumulative with dividends | +86.4% | -66.0% |
| 5-Year ReturnCumulative with dividends | +63.3% | -95.0% |
| 10-Year ReturnCumulative with dividends | +63.3% | -95.5% |
| CAGR (3Y)Annualised 3-year return | +23.1% | -30.2% |
MLYS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MLYS and SPRB each lead in 1 of 2 comparable metrics.
Risk & Volatility
SPRB is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than MLYS's 0.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MLYS currently trades 63.2% from its 52-week high vs SPRB's 24.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MLYSMineralys Therape… | SPRBSpruce Bioscience… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.77x | 0.75x |
| 52-Week HighHighest price in past year | $47.65 | $240.00 |
| 52-Week LowLowest price in past year | $12.59 | $4.35 |
| % of 52W HighCurrent price vs 52-week peak | +63.2% | +24.1% |
| RSI (14)Momentum oscillator 0–100 | 56.8 | 48.5 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 61K |
Evenly matched — MLYS and SPRB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MLYSMineralys Therape… | SPRBSpruce Bioscience… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $46.00 | — |
| # AnalystsCovering analysts | 8 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MLYS leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). SPRB leads in 1 (Income & Cash Flow). 2 tied.
Best OverallMineralys Therapeutics, Inc. (MLYS)Leads 2 of 6 categories
Loading custom metrics...
MLYS vs SPRB: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MLYS or SPRB a better buy right now?
Analysts rate Mineralys Therapeutics, Inc.
(MLYS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MLYS or SPRB?
Over the past 5 years, Mineralys Therapeutics, Inc.
(MLYS) delivered a total return of +63. 3%, compared to -95. 0% for Spruce Biosciences, Inc. (SPRB). Over 10 years, the gap is even starker: MLYS returned +63. 3% versus SPRB's -95. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MLYS or SPRB?
By beta (market sensitivity over 5 years), Spruce Biosciences, Inc.
(SPRB) is the lower-risk stock at 0. 75β versus Mineralys Therapeutics, Inc. 's 0. 77β — meaning MLYS is approximately 3% more volatile than SPRB relative to the S&P 500.
04Which is growing faster — MLYS or SPRB?
On earnings-per-share growth, the picture is similar: Spruce Biosciences, Inc.
grew EPS 47. 5% year-over-year, compared to 37. 4% for Mineralys Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MLYS or SPRB?
Mineralys Therapeutics, Inc.
(MLYS) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Spruce Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLYS leads at 0. 0% versus 0. 0% for SPRB. At the gross margin level — before operating expenses — MLYS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MLYS or SPRB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MLYS or SPRB better for a retirement portfolio?
For long-horizon retirement investors, Mineralys Therapeutics, Inc.
(MLYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). Both have compounded well over 10 years (MLYS: +63. 3%, SPRB: -95. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MLYS and SPRB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.